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Abstract 
Most cells in the body have a constant supply of nutrients, which are required to sustain 
cellular metabolism and functions. In contrast, cells of the immune system can encounter 
conditions with a limited nutrient supply during the course of an immune response. Cells 
of the immune system frequently operate in complex nutrient restricted 
microenvironments such as tumour or inflammatory sites. The concentrations of key 
nutrients such as glucose and certain amino acids, can be low at these sites, and this 
can have an impact upon immune cell function. Nutrient sufficiency is important to 
supply the metabolic and biosynthetic pathways of immune cells. In addition nutrients 
can also act as important cues that influence immunological signalling pathways to affect 
the function of immune cells. This review will describe the various nutrient sensing 
signalling pathways and discuss the evidence that nutrients are critical signals that 
shape immune responses. 
Introduction 
Nutrient restrictive immune microenvironments:  Most tissues are well 
vascularised and replete with nutrients and oxygen. Therefore, under normal 
homeostatic conditions circulating immune cells or those within tissue are adequately 
supplied with the fuels they require to maintain energy homeostasis and cellular 
processes. However, this is not always the case and certain microenvironments can be 
significantly less accommodating. At inflamed sites the influx of inflammatory cells such 
as neutrophils and monocytes increases nutrient consumption and can lead to low 
glucose availability and tissue hypoxia [1]. Neutrophils have low levels of mitochondrial 
respiration and few functional mitochondria and as a result have a high demand for 
glucose to fuel glycolytic energy production as well as to support other cellular 
processes and effector functions [2-4]. At sites of infection there is additional demand for 
nutrients caused by the infecting pathogen. Glucose is an important fuel for many 
pathogenic bacteria, including the common human pathogen Staphylococcus aureus, 
and glucose levels can drop during bacterial infection [5, 6].  Additionally, many virus’ 
have been shown to reprogram the cells they infect towards increased glucose uptake 
and glycolysis to facilitate viral replication [7-11]. The microenvironment within solid 
tumours can also be considerably metabolically restrictive for infiltrating immune cells. 
Tumour cells consume large amounts of glucose, and other nutrients such as glutamine, 
and as a result the tumour microenvironment can become depleted of nutrients [12-15]. 
Additionally, tumour cells and tumour promoting immune cells such as myeloid derived 
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suppressor cells express enzymes such as  arginase and indoleamine-2,3-dioxygenase 
that consume arginine and tryptophan respectively [12, 16]. Solid tumours can also 
become hypoxic due to insufficient vascularisation [17]. As mentioned above, tissue 
hypoxia can be a feature of certain immune microenvironments and while this will not be 
discussed in detail herein, it is the subject of various other review articles [18, 19]. 
 Systemic nutrient alterations: Metabolic syndrome, a health care crisis that is 
reaching epidemic levels world wide, is a clustering of conditions including central 
obesity, dyslipidaemia and hypertension that increases the risks of morbidities such as 
cancer and cardiovascular disease.  Another feature of metabolic syndrome is altered 
immune function [20].  Fatty acids, cholesterol and cholesterol derivatives have all been 
proposed to have roles in controlling immune function and the dysregulated systemic 
levels of these molecules in patients with metabolic syndrome is likely to underpin the 
observed alterations in immune function [21]. The levels of molecules like oxysterols can 
also be altered in discrete immune microenvironments. For instance, tumour cells 
release oxysterols into the tumour microenvironment [22] and activated macrophages 
make large amounts of the oxysterol 25-hydroxycholestrerol (25HC) [23]. It is also clear 
that dietary and microbiome derived molecules such as short chain fatty acids have a 
role to play in the control of immune responses. 
 Therefore, many of the environments in which immune cells operate can have 
variable levels of important nutrients, including glucose, amino acids, fatty acids and 
cholesterol/oxysterols. These molecules are all important for cellular metabolism or as 
structural components of the cell, but importantly, these molecules can also directly 
impact upon immune signalling pathways to influence immune activation, differentiation 
and function. Indeed, there is a growing appreciation that nutrients are important cues 
that can shape immune responses. This review article will discuss the various nutrient 
sensing signalling pathways and the roles they play in regulating the function of immune 
cells. 
 
 
Glucose and Glutamine sensing 
Glucose and glutamine are important fuels that feed into different parts of the ATP 
generating pathways of the cell, glycolysis and oxidative phosphorylation (OxPhos), but 
can also supply various biosynthetic pathways. The levels of these fuels can impact 
upon multiple signalling pathways that are integral to the control of immune responses. 
 
AMPK/mTORC1 signalling:. AMPK is a complex multi-subunit kinase that is an acute 
sensor of cellular energy homeostasis becoming activated in response to an increased 
AMP:ATP ratio that occurs when energy levels are decreased (Figure 1A). Activated 
AMPK functions to restore energy homeostasis by turning off anabolic processes that 
consume ATP (such as fatty acid synthesis) and up-regulating catabolic processes that 
generate ATP (such as glycolysis).  In activated T cells AMPK can be activated within an 
hour of being placed in limiting concentrations of glucose [24, 25]. AMPK is likely to have 
analogous glucose sensing roles in other glycolytic immune cells that are reliant upon 
glucose as a fuel for  generating ATP, such cytokine activated NK cells [26]. AMPK is 
essentially a sensor of the cellular ATP pool, consequently AMPK is likely to be activated 
in a given immune subset when an important ATP generating metabolic pathway is 
disrupted; hypoxia or glutamine deprivation will inhibit OxPhos and thereby activate 
AMPK in immune cells that rely on mitochondrial ATP production. Indeed, glutamine 
deprivation also results in AMPK activation in antigen stimulated T cells, highlighting the 
importance of both glucose and glutamine for ATP production in activated T cells [25]. 
Historically the role of AMPK in the immune system has been slightly controversial with 
conflicting reports when comparing in vitro versus in vivo approaches, and whole body 
knockout versus tissue specific knockout models [24, 27-30]. Studies using 
pharmacological AMPK activators and AMPKα1-/- mice suggested that AMPK has anti-
inflammatory roles; though it should be noted that some of the anti-inflammatory effects 
of these AMPK activators may be AMPK-independent and whole body knockout studies 
can be difficult to interpret [31]. A recent comprehensive and detailed metabolic study in 
T cells demonstrates that AMPK is a key metabolic regulator that provides T cells with 
the metabolic plasticity to adapt to nutrient restrictive conditions such as those found in 
the inflammatory microenvironment. As a result, T cells lacking AMPK have defective 
primary responses to viral and bacterial infection and also show defects in memory 
formation [24, 25]. AMPK also controls the function of mammalian Target of Rapamycin 
complex 1 (mTORC1) as activation of AMPK results in the inhibition of mTORC1 [24, 
25]. mTORC1 is also an important metabolic regulator and has widespread roles in 
controlling immune cell functions [32]. Therefore, glucose or glutamine levels can impact 
upon an AMPK/mTORC1 signalling axis that is important in the control of immune 
responses (Figure 1A). 
 
O-linked β-N-acetylglucosamine transferase (OGT): In addition to supplying glycolysis 
and OxPhos, glucose and glutamine are also used for generation of Uridine diphosphate 
N-acetylglucosamine (UDP-GlcNAc) through the hexosamine biosynthetic pathway 
(HBP); approximately 2-5% of total glucose in the cell is used through the HBP [33]. 
UDP-GlcNAc is utilized by glycosyltransferases for various cellular processes including 
O-GlyNAcylation, the reversible addition of N-acetylglucosamine (GlcNAc) to proteins on 
serine or threonine residues. O-linked GlcNAc transferase (OGT) adds GlcNAc to 
proteins while O-linked GlcNAc hydrolase (OGA) removes the GlcNAc from 
serine/threonine residues. O-GlcNAcylation has emerged as one of the most abundant 
post-translational modifications that can control many aspects of protein function 
including stability, localization and transcriptional activity [34, 35]. O-GlcNAcylation can 
compete with protein phosphorylation as both types of modification target serine and 
threonine residues on a protein. As a result, there can be extensive crosstalk between 
these two protein modification pathways [36-38]. Levels of UDP-GlcNAc and protein O-
GlcNAcylation are dependent on the supply of both glucose and glutamine in T cells 
arguing that OGT and O-GlcNAcylation are important nutrient sensing mechanisms in 
these cells [39]. OGT is essential for normal T cell development, activation and clonal 
expansion [39, 40]. A number of signalling molecules that are important for T cell 
function are found to be O-GlcNAcylated including c-Myc, NFAT and NF-κB (Figure 1B) 
[39-41]. c-Myc is O-GlcNAcylated on a threonine residue that can also be 
phosphorylated by the kinase GSK3; phosphorylation on this site promotes c-Myc 
degradation and O-GlcNAcylation of this residue is predicted to stabilize c-Myc protein 
[42, 43]. Indeed, OGT and O-GlcNAcylation are essential for sustaining c-Myc protein 
expression in CD8 cytotoxic T cells [39]. Given the number of proteins that appear to be 
O-GlcNAcylated in T cells it is likely that other proteins are involved in mediating the 
important role observed for OGT in CD8 T cells [39]. While this protein modification has 
not been studied in depth in other immune cell subsets, there is evidence to suggest that 
glucose/glutamine dependent O-GlcNAcylation has an important role for other aspects of 
immune function. LPS induces an increase in O-GlcNAcylation of numerous proteins in 
the RAW 264.7 macrophage cell line and this has been liked to cytokine production [44]. 
The pattern recognition receptor Nod2 has been shown to be O-GlcNAcylated resulting 
in altered downstream signalling to NF-κB [45]. Indeed, there are also multiple reports 
that NF-κB can be directly regulated by O-GlcNAcylation on multiple residues [40, 41, 
46, 47]. An increase in protein O-GlcNAcylation is also observed upon activation of 
neutrophils which has been linked to neutrophil motility [48, 49]. 
 
Glycolytic flux links glucose to immune signalling: Glucose is the substrate for glycolysis 
and so it follows that flux through this metabolic pathway is sensitive to the levels of 
glucose available. The flux through glycolysis can impact upon immunological signalling 
pathways and affect immune function in a number of ways. The glycolytic metabolite 
phosphenolpyruvate (PEP) can affect Ca2+  signalling and the activation of the nuclear 
factor of activated T cells (NFAT) transcription factor in antigen stimulated T cells. PEP 
represses sarco/ER Ca2+-ATPase (SERCA) activity, which is responsible for Ca2+ 
reuptake into the ER; therefore, PEP enhances cytosolic Ca2+ signalling and promotes 
NFAT nuclear activity. T cells activated in low glucose have reduced PEP levels, 
reduced cytostolic Ca2+ signalling and reduced nuclear NFAT, leading to defective T cell 
activation (Figure 1C) [14]. The function of the glycolytic enzyme glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is also sensitive to glycolytic flux in T cells. GAPDH 
has additional roles outside its function as a glycolytic enzyme including acting an RNA 
binding protein to inhibit the translation of certain proteins including IFNγ and IL2 in T 
cells. The rate of glycolytic flux in activated T cells controls the balance of these different 
GAPDH functions; high rates of glycolysis prevent GAPDH binding to IL2 and IFNγ 
mRNA and thereby maximize the production of these cytokines (Figure 1D). On the 
other hand, if glucose is limiting, reduced glycolytic flux allows GAPDH to inhibit IFNγ 
and IL2 production [50].  In myeloid cells GAPDH is a component of the IFNγ-activated 
inhibitor of translation (GAIT) complex that binds defined 3' untranslated region (UTR) 
elements within a family of inflammatory mRNAs and suppresses their translation, 
though it is not yet clear whether GAPDH’s role in the GAIT complex is affected by 
glucose or glycolytic flux [51].  
 
 
 
Amino acid sensing 
 
Amino acids are important for biosynthetic pathways in immune cells, including protein 
and nucleotide synthesis. Furthermore, they can also be directly metabolised to 
generate immunomodulatory molecules such as nitric oxide; arginine is a substrate for 
inducible nitric oxide synthase (iNOS). Thus, it is not surprising that immune cells, in 
particular lymphocytes, greatly increase amino acid uptake in response to immune 
stimulation. Amino acids of particular importance to lymphocytes include glutamine, 
methionine, tryptophan, arginine, and leucine. Depletion of any of these amino acids 
results in impaired responses to immune activation [16, 52-55]. T lymphocytes increase 
nutrient uptake in response to antigen stimulation through up-regulating the expression 
of nutrient transporters. This is critically important in the generation of effector cells, 
indeed T cells lacking the glucose transporter Glut1, the large neutral amino acid 
transporter Slc7a5, or the glutamine transporter Asct2 fail to differentiate into effector 
cells [56-59]. In addition to the role for amino acids as cellular fuels, certain amino acids 
can also be considered important signalling molecules; a number of signalling pathways 
important for immune responses are acutely sensitive to changes in the levels of certain 
amino acids and are discussed below. 
 
 
Amino acids and mTORC1: In recent years the serine threonine kinase mTORC1 has 
emerged as a central regulator of immune cell function.  mTORC1 has diverse roles in 
controlling the function of immune cells in both the adaptive and innate arms of the 
immune system [32, 60]. For instance, in T cells mTOR signalling is essential for lineage 
commitment of Th1 and Th17 effector cells, whilst in macrophages Rheb-dependent 
activation of mTORC1 has been implicated in the monocyte-macrophage differentiation 
and mature macrophage phagocytosis [61-63]. The regulation of this kinase complex is 
complicated; mTORC1 activity turned on by growth factor or antigen signalling and 
switched off by other signalling pathways including AMPK, as described above (Figure 
2A). However, mTORC1 activity is also acutely sensitive to the availability of certain 
amino acids and this arm of mTORC1 regulation overrides other signalling pathways; in 
the absence of amino acids mTORC1 is turned off even in the presence of strong growth 
factor signalling (Figure 2). Recent advances have begun to unravel the systems 
through which mTORC1 activity is controlled by amino acid availability in mammalian 
cells. Amino acids act through various amino acid sensors that promote the activity of 
the Rag GTPases to facilitate mTORC1 activation [64]. Cytosolic sensors for leucine and 
arginine have been identified as Sestrin2 and Castor, respectively [65, 66], and the 
solute transporter Slc38a9 has been identified as a lysosomal arginine sensor [67, 68]. 
In activated lymphocytes, mTORC1 activity is exquisitely sensitive to leucine availability 
[57]. The importance of leucine abundance on the regulation of mTORC1 activity in T 
lymphocytes is further highlighted by studies in mice lacking the leucine metabolizing 
enzyme BCATc (cytosolic branched-chain aminotransferase). Activated T cells from 
these mice have higher intracellular leucine concentrations and show increased 
mTORC1 activity compared to WT controls [69].  While the data clearly shows that 
leucine is essential for mTORC1 activity in immune cells, the evidence for a similar 
sensitivity to arginine is lacking. Activated T cells do not seem to be acutely sensitive to 
arginine deprivation as is the case for leucine [57, 70]. Interestingly, effector T cells up-
regulate Slc7a5 mediated amino acid transport in response to arginine deprivation [71]. 
Therefore, it is tempting to speculate that this response may be a compensatory 
mechanisms to sustain mTORC1 activity in the absence of arginine by increasing 
leucine influx. More work will be required to elucidate the respective roles for arginine 
and leucine sensing in immune cells but it seems likely that mTORC1 activity may have 
differential sensitivities to arginine and leucine in distinct immune cell types. 
Glutamine availability is also essential for mTORC1 activity in activated lymphocytes; 
acute glutamine deprivation has an equivalent inhibitory effect on mTORC1 to leucine 
deprivation [57, 58]. This is because glutamine is required for efficient leucine uptake 
into these cells through the Slc7a5 amino acid transporter (Figure 2B) [57, 58, 72]. 
Slc7a5 is an obligate antiporter: one amino acid in, one amino acid out. Slc7a5 has high 
import affinities for large neutral amino acids including leucine, valine, tryptophan and 
methionine and a high export affinity for glutamine [73]. 	Thus, in the context of amino 
acid sensing and the impact on mTORC1, Slc7a5 will transport glutamine out of the cell 
whilst importing leucine into the cell (Figure 2B).	
 
 
Amino acids and c-Myc: The transcription factor c-Myc (myelocytomatosis oncogene) is 
a key controller of the metabolic reprogramming seen in T cells in response to antigen 
stimulation [74] as well as macrophages responding to M-CSF [75]. One role for c-Myc is 
to promote or sustain the expression of a cohort of nutrient transporters, including 
glucose transporters, amino acid transporters and the transferrin receptor (CD71). The 
importance of iron transport for lymphocyte function is evident in patients that have a 
missense mutation in their transferrin receptor. These patients have severe 
immunodeficiency characterised by impaired T and B cell function [76]. 
Constitutively active c-Myc mutations are a common occurrence in cancers, thus it is 
understandable that lymphocytes have mechanisms in place to ensure tight control of c-
Myc expression. c-Myc protein has a very short half life in lymphocytes and sustained 
expression of c-Myc is only possible in cells that have high rates of amino acid uptake 
and protein synthesis [39, 43, 57]. Also, as mentioned above, c-Myc levels are 
dependent on glutamine fuelled O-GlcNAcylation in effector T cells [39]. c-Myc protein 
expression is effectively “fine-tuned” by amino acid availability, which is dependent on  
amino acid levels in the local microenvironment and levels of amino acid transporter 
expression. This mechanism for regulating c-Myc expression is important for immune 
responses. For example, during the first division of antigen activated T cells there is 
unequal distribution of the amino acid transporter Slc7a5 between the daughter cells. As 
a result the daughter cell proximal to the antigen presenting cell (APC) has increased 
amino acid uptake, c-Myc expression and mTORC1 activity compared to the distal 
daughter cell [77, 78]. This asymmetric distribution of c-Myc and mTORC1 activity leads 
to distinct  metabolic signatures in each daughter cells and is thought to contribute to 
effector versus memory T cell differentiation [77, 78].  
 
 
General control non-derepressible 2 kinase (GCN2): The integrated stress response in 
eukaryotic cells can be induced by various stimuli, including ER stress, presence of 
dsRNA, oxidative stress and amino acid deprivation. The common response to these 
cellular stresses is to enforce a general down-regulation of protein synthesis and 
switching on autophagy, whilst driving increased translation and expression of certain 
transcription factors, such as ATF4. This is achieved by inactivation of the eukaryotic 
initiation factor 2a (eIF2a) following phosphorylation by stress sensing kinases. The 
serine/threonine protein kinase GCN2 senses low cellular amino acid levels through 
binding to uncharged transfer RNA (tRNA) leading to kinase activation and subsequent 
phosphorylation of eIF2a (Figure 2C)[79].   
In dendritic cells, GCN2 activiation in response to virus (or live virus vaccination) 
enhances antigen presentation to CD8 cells [80]. Conversely, GCN2 activity in gut APC 
restrains excessive Th17 responses; mice lacking GCN2 develop stronger Th17 
responses and more severe colitis than WT controls, in an induced colitis model [81]. 
APCs in the GCN2-null mice show defective autophagy and excessive ROS 
accumulation resulting in enhanced inflammasome activation [81]. Thus, amino acid 
levels and GCN2 signaling acts to balance the immune response by inducing autophagy 
and cross-presentation of viral antigens in APCs and limiting excessive ROS 
accumulation and inflammasome activity during cellular stress. Amino acid sensing by 
GCN2 is also important for lymphocytes. The enzyme Indoleamine 2,3-dioxygenase 
(IDO) suppresses T cell responses, at least in part, by depleting tryptophan levels 
leading to the activation of GCN2 within the T cell (Figure 2C). Activation of GCN2 in 
CD8 T cells results in proliferative arrest and anergy, while in CD4 T cells GCN2 
activation can lead to the generation of regulatory T cells [82, 83]. Studies using murine 
EAE show that mice with GCN2-null T cells have a lower frequency of regulatory Tregs 
in the CNS and subsequently develop worse symptoms than WT control mice [84, 85]. 
 
 
 
Fatty acid sensing and immune function 
Free fatty acids (FFA) are aliphatic chains of varying carbon length that can be saturated 
or unsaturated containing a carboxylic acid [86]. Free fatty acids can be obtained 
exogenously through diet, produced by the gut microbiome and can also be produced 
from breakdown of triacylglycerides in the liver and adipose tissue. While FFA can be 
used as a cellular fuel for generating ATP, they also act as ligands for several g protein 
coupled receptors (GPCR) [87]. Many immune cells types have been demonstrated to 
express GPCR receptors for FFA including macrophages, neutrophils, T cells and 
dendritic cells  [86]. These receptors can be classified based on the carbon number of 
their fatty acid ligands. GPR40 and GPR120 (also called Fatty acid receptor (FFAR) 1 
and FFAR4, respectively) are responsive to long-chain fatty acid (LCFA, >C12), GPR43, 
GPR41 (also called FFAR2 and FFAR3 respectively) are activated by short-chain fatty 
acids (SCFA, C2-C6) [88]. GPR109a (also called Hydroxycarboxylic Acid Receptor 2) is 
ligated specifically by the 4 carbon SCFA butyrate [89]. Medium-chain fatty acids (MCFA 
C9-14) appear to signal through GPR84 and also GPR40 [90, 91]. 
SCFA sensing: SCFA, such as acetate, propionate and butyrate, can be produced by a 
number of tissues, notably the liver, but the major source of SCFA is the gut microbiome. 
SCFA are metabolic by-products of intestinal microbiota fermentation that can be taken 
up by the gut and reach the circulation via the portal vein and the liver [92]. SCFA 
produced in the gut are used as a fuel source for certain cells including colonic epithelial 
cells; in germ free mice colonic epithelial cells are severely nutrient and energy deprived 
[93]. Microbiome derived SCFA are also important fuels for B cell responses; SCFA fuel 
energy producing pathways in B cells and boost antibody responses [94]. Mice with low 
SCFA production due to microbial insufficiency were defective for pathogen-specific 
antibody responses, while a SCFA supplemented diet restored normal B cell responses 
[94]. SCFA can also function as potent signalling molecules that have an anti-
inflammatory effect on the function of immune cells. Indeed, SCFA may have therapeutic 
uses for inflammatory diseases such as colitis; colonic irrigation with SCFA has showed 
some benefit for patients with colitis and in mice, acetate in the drinking water markedly 
reduced colitis severity [95-97]. SCFA signalling through the GPCRs GPR43, GPR41 
and GPCR109a (Figure 3A); GPR41 is expressed primarily on adipocytes, GPR43 is 
highly expresses on polymorphonuclear leukocytes (PMNs) and lymphocytes, and  
GPR190a is expressed on various immune cells including neutrophils and macrophages 
but not lymphocytes [98-103]. SCFA can impact upon the differentiation of both CD4 and 
CD8 T subsets, promoting CD4 regulatory T cell (Treg) formation and optimal CD8 
memory T cell responses [104, 105]. Tregs are important in maintaining immune 
homeostasis and Tregs numbers in the colon lamina propria are dependent on the gut 
microbiome; germ free mice have dramatically reduced Treg numbers in the colon [105, 
106]. Microbiome derived SCFA are important in promoting Treg formation in the colon 
through multiple mechanisms; directly through ligating Treg expressed GPR43 [99]; and 
indirectly though ligating GPR109a on macrophages and DCs to induce the expression 
of IL10 [107]. SCFA also suppress the production of pro-inflammatory mediators from 
neutrophils, such as TNFα and nitric oxide [108]. Additionally, SCFA can have direct 
actions in the cells independent of GPRs, notably SCFA can impact upon the levels of 
protein acetylation. Acetate is converted to acetyl-CoA, the substrate for  acetylation 
reactions, while butyrate and propionate are inhibitors of histone deacetylases (HDAC) 
(Figure 3A). Elevated levels of acetate promotes the acetylation of the glycolytic enzyme 
GAPDH facilitating elevated glycolytic flux and robust CD8 memory T cell responses 
[104]. Butyrate and propionate mediated inhibition of HDACs affects histone acetylation 
in T cells; butyrate/propionate promotes acetylation at the FoxP3 locus in Tregs inducing 
FoxP3 protein expression [109, 110]. SCFA-mediated inhibition of HDACs also 
potentiates the ability of DCs to promote Treg differentiation and inhibits pro-
inflammatory macrophage and neutrophil function [108, 111]. HDACs can also 
deacetylate non-histone targets including NFκB, which may also be important for the 
anti-inflammatory actions of butyrate and  propionate [112]. 
LCFA sensing: GPR120 is strongly activated by omega 3 fatty acids including the 
essential fatty acid, α-linoleic acid which is not endogenously synthesised; therefore 
GPR120 is important in responding to diet obtained fatty acids [113]. GPR120 is highly 
expressed in CD11c+ macrophages and adipocytes [114]. Exogenously derived omega 
3 fatty acids, including docosahexaenoic acid (C22, DHA) and eicosapentaenoic acid 
(C20, EPA) have clear anti-inflammatory effects on macrophages. Ligation of GPR120 
by DHA results in decreased TLR2/3/4 and TNFα mediated signal transduction leading 
to reduced proinflammatory cytokine production (TNFα, IL6, IL1β) [114, 115].  The anti-
inflammatory function of GPR120 involves the sequestration of TAB2 to bind to β-
Arrestin-2 rather than TAK1, leading to decreased TAK1 signalling and decreased NFκB 
and JNK activation (Figure 3B)[114]. There is also evidence that LCFA inhibit the 
activation of the NLRP3 inflammasome; DHA acting through GPR120, and also GPR40, 
supresses caspase 1 cleavage and IL1-β secretion in macrophages by increasing β-
arrestin-2 binding to NLRP3 (Figure 3B)[115].  
 
MCFA sensing: While the effect of MCFA on the immune response has not been 
extensively studied, there is evidence that MCFAs such as capric acid, undecanoic acid 
and lauric acid can impact upon the function of certain immune cells. The MCFA 
receptor GPR84 is highly expressed on macrophages and neutrophils; LPS stimulated 
macrophages also show strong induction of GPR84 expression [90]. The data suggests 
that MCFA, acting through GPR84, can enhance LPS-induced IL-12 and TNFα 
expression in macrophages [90, 116]. Ligation of GPR84 also induces the production of 
IL8 and chemotactic responses in human polymorphonuclear leukocytes [116]. 
Therefore, the data available suggests that, in contrast to SCFA and LCFA, MCFA have  
proinflammatory effects on immune cell function.  
 
 
CD36 scavenging receptor. CD36 is a well characterised receptor for triacylglycerol 
substrates and is highly expressed in scavenging immune cells such as macrophages 
[117]. CD36 is responsible for receptor mediated endocytosis of triacylglycerol-rich 
lipoprotein particles, such as low density lipoproteins (LDL) and very low density 
lipoproteins (VLDL), and also has a high affinity for oxidised LDL (oxLDL) [118-120]. 
Triglycerides can be used to generate intracellular FFA to fuel OxPhos following fatty 
acid oxidation in the mitochondria (Figure 3C). Macrophage polarisation to M1 or M2 
phenotypes is closely linked to cellular metabolism; M1 macrophages rely on glycolysis 
while M2 are fuelled by fatty acid oxidation and OxPhos. IL-4 induced CD36 is crucial for 
generating M2 macrophages; CD36 deficiency disrupts M2 macrophage metabolism and 
polarisation [121]. Therefore, CD36 expression can affect immune function by supplying 
cellular metabolic pathways, but additionally CD36-mediated scavenging can also 
directly impact upon immune signalling pathways (Figure 3C). In macrophages, CD36 
mediates the internalisation of various molecules, such as oxLDL, and the subsequent 
lysosomal conversion of these molecules into crystals, such as cholesterol crystals, that 
then activate the NLRP3 inflammasome to promote IL1β production [122]. In addition, 
through an undefined mechanism CD36 augments TLR4-6 signalling to prime the 
inflammasome, inducing the expression of inflammatory genes including IL1β and 
NLRP3 (Figure 3C)[122]. In macrophages, ligation of CD36 with oxLDL also leads to the 
recruitment of the plasma membrane ion transporter Na+/K+ ATPase and the subsequent 
activation of the Src family kinase Lyn [123]. Therefore, CD36 is important in controlling 
macrophage function through supporting the oxidative metabolism of fatty acids and also 
through promoting inflammatory signalling.  
 
 
 
Cholesterol and Oxysterol sensing and immune function 
 
Cholesterol is an important component of the plasma membrane that is involved in 
maintaining membrane integrity and fluidity, but cholesterol also has roles in signal 
transduction. There are multiple branches off the cholesterol biosynthesis pathway that 
generate intermediates that are important for steroid hormone production, protein 
prenylation and also have direct effector and regulatory roles in the immune response 
[124]. Cholesterol can also be oxidized into various oxysterol molecules, such as 25HC, 
that are important in the control of various aspects of the immune cell function. 
Cholesterol, oxysterols or indeed flux through the cholesterol biosynthesis pathway can 
directly regulate signal transduction pathways including those involved in the type 1 
interferon response. While oxysterols have a substantially shorter half-life to cholesterol 
there is evidence that the levels of these molecules can accumulate in discrete immune 
microenvironments [22, 23].  In particular, activated macrophages and tumour cells have 
been shown to produce and secrete oxyterols; activated macrophages upregulate the 
expression of cholesterol 25-hydroxylase (CH25H) and produce large amounts of 25HC 
while tumour cell secrete a number of different oxysterol species [22, 23]. Macrophage 
derived 25HC can have direct immunoregulatory effects, 25HC affects the plasma 
membranes of host cells to suppress viral fusion, but many of the immunoregulatory 
effects of 25HC on the immune response are through changes in signalling pathways 
[125]. Under certain conditions systemic levels of oxysterols can also be elevated. 
Patients with aspects of metabolic syndrome, hypercholesteremia, type II diabetes or 
hyperlipidemia, have elevated plasma levels of oxidized cholesterol species [126, 127]. 
Healthy individuals injected with LPS showed increased plasma levels of 25HC, arguing 
that inflammatory processes can also promote elevated levels of systemic oxysterols 
[128]. This section will describe the signal transduction pathways that are sensitive to 
levels of cholesterol and oxysterols and the role they play in controlling immune 
responses.  
 
 
Srebp signalling: The Sterol response element binding proteins (Srebp) are transcription 
factors that are the master regulators of fatty acid and cholesterol synthesis as they 
promote the expression of most of the enzymes in these biosynthetic pathways [129]. 
Srebp transcription factors are activated through a complex mechanism that involves the 
transport of a precursor Srebp protein from the endoplasmic reticulum (ER) to the Golgi 
apparatus, multiple protease cleavage events and the subsequent translocation of the 
cleaved active transcription factor to the nucleus (Figure 4A). One key regulator of this 
process is Srebp cleavage-activating protein (SCAP) that escorts Srebp from the ER to 
the Golgi [130]. SCAP contains a sterol-sensing domain and acts as a cholesterol 
sensor; cholesterol binding induces a conformational change in SCAP that promotes its 
interaction with the ER anchoring INSulin-Induced Gene (INSIG)  proteins, thus retaining 
SCAP and Srebp in the ER [131, 132]. The oxysterol 25HC interacts with INSIG rather 
than SCAP but with the same result, the SCAP and INSIG interaction is promoted 
leading to the retention of SCAP/Srebp in the ER (Figure 4A)[133]. In addition to the role 
for Srebp transcription factors in controlling fatty acid and cholesterol biosynthetic 
pathways, Srebp has been described to have a number of direct immunoregulatory 
roles. The Srebp1a isoform is required for the inflammatory functions of macrophages, 
such as IL1β production, through promoting the expression of the inflammasome 
component Nlrp1a; Srebp1a deficient mice are resistant to LPS induced sepsis [134]. 
Srebp1c has been linked to the regulation of IL17 expression in Th17 T cells [135]. The 
SCAP/Srebp signaling axis has also been shown to be an important factor in anti-viral 
responses in macrophages. Genetically disrupting this Srebp activation through deleting 
SCAP specifically in macrophages is sufficient to render mice resistant to viral challenge. 
This is because changes in flux through the cholesterol biosynthetic pathway impact 
directly upon type 1 interferon signalling; decreased synthesized cholesterol in the ER 
results in the activation of STING/TBK1 signalling to induce IRF3 activity and the 
expression of interferon regulated genes (Figure 4B) [136]. Another reason why flux 
through the cholesterol biosynthetic pathway is likely to be important is because 
intermediates in this pathway can act as agonists for RORγt transcription factors and so 
impact upon the differentiation of Th17 CD4 T cells [137, 138].	   
 
Inflammasome activation: Cholesterol crystals can potently affect immunological 
signaling pathways. Free cholesterol has very low solubility in aqueous environments 
and for this reason cholesterol is complexed to apoproteins for transport in the 
bloodstream. However, in pathologies such as atherosclerosis, elevated levels of free 
cholesterol result in the formation of cholesterol crystals within arterial plaques and 
within the macrophages at these sites. These cholesterol crystals stimulate inflammatory 
signalling pathways through activation of the NLRP3 inflammasome [139]. As mentioned 
above, CD36 is important for inflammatory signalling in macrophages due to its function 
as a lipid transporter but also due to its interaction with inflammatory signalling 
pathways. Indeed, CD36 seems to be particularly important for the formation of 
cholesterol crystals in macrophages in the context of atherosclerosis (Figure 4C)[139]. 
Targeting CD36 in atherosclerotic mice resulted decreased inflammasome activation, 
lower serum concentrations of IL-1β and decreased concentrations of cholesterol 
crystals in the atherosclerotic plaques [122]. 
 
 
 
Oxysterols as ligands for nuclear receptors:  A number of different oxysterol species, 
including  22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol and  27-hydroxy-
cholesterol, are ligands for Liver X receptors (LXRs) [140]. LXRs forms a permissive 
heterodimer with retinoid X receptor (RXR) and regulate transcription through binding to 
LXR response elements [141]. In the absence of ligand LXRs act as transcriptional 
repressors but switch into transcriptional activators when ligand in bound. LXRs are best 
characterized as important regulators of systemic sterol homeostasis and control the 
expression of a panel of genes involved in sterol transport between cells and tissues 
[140]. Importantly, LXRs are also described to have important immunoregulatory roles. 
Mice deficient in LXRs spontaneously develop a lupus-like autoimmune condition 
arguing that LXRs are important for the maintenance of self tolerance [142]. This is 
explained, at least in part, because in macrophages LXRs facilitate the phagocytosis and 
clearance of apoptotic cells, LXRs promote cholesterol efflux to prevent lipotoxicity,  and 
LXRs inhibit the expression pro-inflammatory genes by suppressing NF-κB and AP1 
activities [142]. LXRs are also important for maintaining neutrophil homeostasis, and in 
lymphocytes LXR agonists inhibit mitogen driven proliferation [143, 144]. Additionally, 
LXRs have a role in the differentiation of different CD4 T cells subsets; LXR agonists 
inhibit the Th17 differentiation through a mechanism that involves Srebp1c/Aryl 
hydrocarbon receptor-mediated inhibition IL17 expression  [135, 145]. LXR agonists 
have also been described to inhibit IgE production in human and murine B cells [146].  
Oxysterols are also agonists for RORγt, which is required for Th17 T cell differentiation. 
The oxysterol, 7β,26-dihydroxycholesterol (7β,26-HC), has been identified as a potent 
RORγt agonist and enhances the differentiation of Th17 CD4 T cells in mice and 
humans [147]. Mice deficient in CYP27A1, a key enzyme in generating 7β,26-HC, have 
decreased formation of both CD4 Th17 T cells and IL17 producing γδ T cells [147].  
 
Other signalling effects of oxysterols: 25HC can be further oxidised to 7α,25-
Dihydroxycholesterol (7α,25diHC) by CYP7B1 [148], which has been identified as a 
potent agonist of the G protein-coupled receptor EBI2 (also called GPR183) [149, 150].  
7α,25HC signalling through EBI2 acts as a chemoattractant that directs the migration of 
multiple immune cell subsets and is important for adaptive immune responses, such as 
T cell-dependent antibody responses [149, 150]. Another study showed that 25HC 
amplifies inflammatory signalling in macrophages by recruiting AP1 transcription factors 
to TLR responsive genes [151].  In this study 25HC was found to be involved in 
inflammatory-induced pathology of influenza infection.  
 
  
Final remarks: 
The phrase “you are what you eat” has been used for some time to convey the idea that 
ones diet, healthy or otherwise, has a big influence on ones wellbeing. It is now 
becoming clear that this phrase also resonates at the cellular level with respect to our 
immune cells. The identity of an immune cell, the pro and anti-inflammatory 
characteristics of immune cells, can be significantly influenced by the nutrients that are 
available to it in the local microenvironment. At the same time there is an increasing 
appreciation that there is an inflammatory component to the majority of diseases. A 
detailed understanding of the relationship between nutrients and immune responses is 
likely to reveal exciting opportunities for developing new approaches to promote health 
and wellbeing and to treat inflammatory disease.  
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Figure Legends: 
 
Figure 1: Glucose and Glutamine sensing pathways. (A) Glucose and Glutamine are 
important fuels for the ATP generating pathways, glycolysis and mitochondrial OxPhos. 
AMPK is an energy sensing kinase whose activity is sensitive to the ratio of ATP to 
AMP. Once activated, AMPK turns off the key metabolic regulator mTORC1. (B) 
Glucose and glutamine are both required to supply the hexosamine biosynthesis 
pathway (HBP). This pathway generates UDP-GlcNAc, the substrate for the enzyme O-
GlcNAc transferase (OGT) that is responsible for O-GlcNAcylation, the addition of N-
acetyl-glucosamine to proteins.  O-GlcNAcylation in immune cells controls the activity of 
a number of key signalling molecules including c-Myc and NFκB. (C) The glycolytic 
intermediate phosphoenolpyruvate (PEP) can inhibit the activity of the SERCA Ca2+ 
channels that are involved in Ca2+ reuptake and the termination of cytosolic Ca2+ 
signalling. Under glucose replete conditions PEP sustains Ca2+ mediated activation of 
NFAT, facilitating T cell activation. When glucose is limiting, Ca2+ signaling and NFAT 
activation is restricted. (D) GAPDH has multiple roles in the cell, acting as a glycolytic 
enzyme and also a RNA binding protein. GAPDH binding to IFNγ and IL2 mRNA inhibits 
the translation of these cytokines. Under glucose replete conditions GAPDH is engaged 
in glycolysis and is not available to inhibit the translation of IFNγ and IL2. When glucose 
is limiting, GAPDH is available to bind to IFNγ and IL2 mRNA and inhibit the expression 
of these cytokines. 
 
Figure 2: Amino acid sensing pathways. (A) The activation of mTORC1 requires both 
the localization of mTORC1 to the lysosomal membrane, which is controlled by amino 
acid availability, and the activation of the the GTPase Rheb, which is controlled by 
multiple signaling pathways that converge on the GTPase activating protein TSC2. 
mTORC1 localized to the lysosome is in a complex with multiple members of the Rag 
GTPase family, Ragulator and v-ATPase. The activity of the Rag GTPases, and so 
mTORC1 recruitment to the lysosome, is controlled by the cytosolic amino acid sensors; 
CASTOR,  (cytosolic arginine sensor) and  Sestrin 2 (cytosolic leucine sensor). 
Lysosomal arginine can also impact upon mTORC1 localisation to the lysosomal 
membrane through Slc38a9. TSC2 inactivates Rheb as it promotes the hydrolysis of 
Rheb bound GTP to GDP. Multiple signalling pathways control Rheb mediated mTORC1 
activation through controlling TSC2 activity. These include growth factor stimulated 
signalling pathways (PI3-kinase/Akt, Erk, p90RSK), which inhibit TSC2 thus activating 
mTORC1, and stress activated pathways such as AMPK, which promote TSC2 activity 
thus inhibiting mTORC1. (B) While leucine and arginine are directly sensed by the 
cytosolic sensors Sestrin 2 and CASTOR, glutamine is required for mTORC1 indirectly.  
Glutamine is important for mTORC1 activity because it facilitates Slc7a5-mediated 
leucine uptake. Slc7a5 is an obligate anti-porter and must transport a glutamine out of 
the cell to import leucine. (C) GCN2 is a general amino acid sensor that is activated by 
uncharged tRNA molecules that accumulate when amino acid concentration drop. 
Tryptophan levels can become limiting in various inflammatory microenvironments due 
to the action of IDO that is expressed by various cells including tumour cells and myeloid 
derived suppressor cells; reduced tryptophan levels lead to GCN2 activation.   
 
 
 
 
Figure 3: Free Fatty acid sensing pathways.  (A) Short chain fatty acids (SCFA) bind 
to the G protein linked receptors GPR41 and GPR43; the 4 carbon SCFA butyrate also 
binds to GPR109a. Acetate can directly impact upon cell signalling as it can be 
converted to Acetyl-CoA, the substrate for protein acetylation reactions; elevated acetate 
promotes GAPDH acetylation and elevated glycolysis. Butyrate and proprionate also 
promote protein acetylation as they are inhibitors of the HDAC deacetylases. HDACs 
deacetylate histones as well as non-histone substrates including NFκB. Butyrate or 
propionate mediated inhibition of HDACs promotes FoxP3 expression in T cells. (B) 
Long chain fatty acids (LCFA) have anti-inflammatory effects, signaling through GPR40 
and GPR120 receptors to inhibit the proinflammatory NFκB and JNK signalling pathways 
and to inhibit the NLRP3 inflammasome through a mechanism involving βarrestin2. (C) 
CD36 mediates receptor mediated endocytosis of triglyceride rich lipoproteins. FFA 
released following lipolysis of triglycerides can be converted to acetyl-CoA by β-oxidation 
to fuel OxPhos (i). oxLDL binding to CD36 acts together with TLR4-TLR6 to prime the 
NLRP3 inflammasome inducing the expression of IL1β and NLRP3 mRNA (ii). Binding of 
oxLDL can induce the interaction of CD36 with the plasma membrane Na+/K+ ATPase 
leading to the initiation of intracellular signalling and the activation of the src family 
tyrosine kinase Lyn (iii). 
 
Figure 5: Cholesterol and oxysterol sensing pathways. (A) Srebp is synthesized as 
a integral membrane protein localized to the ER. Generation of activate Srebp 
transcription factors requires SCAP-mediated translocation of Srebp to the Golgi ➀ 
followed by two cleavage events mediated by site-1 protease (S1P) and site-2 protease 
(S2P). The result is the release of soluble Srebp that can translocate to the nucleus ➁ 
and promote the expression of target genes that contain Srebp response elements 
(SRE). Cholesterol binds to SCAP and promotes the interaction of SCAP with the ER-
anchored protein INSIG, preventing Srebp translocation to the Golgi. 25HC binds to 
INSIG and also promotes the SCAP:INSIG interaction preventing Srebp activation. (B) 
Synthesized cholesterol in the ER negatively impacts upon type 1 interferon signalling. 
Decreased cholesterol synthesis results in STING/TBK1-mediated activation of IRF3 and 
the induction of interferon sensitive genes. (C) CD36 mediated endocytosis of oxLDL 
can lead to the formation of cholesterol crystals in the lysosome and lysosomal 
destabilization leading to the activation of the NLRP3 inflammasone and caspase 1 
mediated cleavage of proIL1β to generate mature IL1β. (D) LXR are nuclear receptors 
that form a permissive heterodiamer with RXR and bind to LXR response elements 
(LXRE). In the absence of ligand LXR/RXR act as transcriptional repressors. Oxysterol 
ligands bind to LXR and convert the LXR/RXR diamer into a transcriptional activator. 
The oxysterol 7β,26-dihydroxycholersterol  (7β,26-HC) acts as an agonist for the RORγt 
transcription factor, which is required for Th17 T cell differentiation. 
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